Clinical Trial Update: Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating consolidative therapy with ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia/small …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• METHYLPREDNISOLONE (methylprednisolone)
• Ofatumumab (ofatumumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2021-12-02